sellWeak cluster of 310b5-1 plan
Brian Baranick sold $200k of EXAS
EVP, GM, Precision Oncology at EXACT SCIENCES CORP. 2,858 shares at an average of $70.08, traded Nov 4, 2025, filed Nov 6, 2025.
Warning score
27Value
$200k
2,858 shares
Holdings after
22,368
-11% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +12Trade size$200k at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-270166, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | SOpen-market sale Common Stock10b5-1 | -2,858 | $70.08 | $200k | 22,368 | Nov 6, 2025 |
Related signals
Other insiders at EXACT SCIENCES CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | EXACT SCIENCES CORP | James Herriott SVP, General Counsel & Sec | $70k 1,000 shares | -8% | |
| 24Weak | EXACT SCIENCES CORP | Jacob A Orville EVP, GM, Screening | $375k 5,000 shares | -18% | |
| 25Weak | EXACT SCIENCES CORP | James Herriott SVP, General Counsel & Sec | $105k 1,500 shares | -11% | |
| 37Weak | EXACT SCIENCES CORP | Katherine S Zanotti director | $780k 12,000 shares | -16% | |
| 13Weak | EXACT SCIENCES CORP | James Edward Doyle director | $120k 2,000 shares | -3% | |
| 12Weak | EXACT SCIENCES CORP | James Herriott SVP, General Counsel & Sec | $90k 1,500 shares | -10% | |
| 2Weak | EXACT SCIENCES CORP | James Edward Doyle director | $62k 1,485 shares | -2% | |
| 6Weak | EXACT SCIENCES CORP | Katherine S Zanotti director | $171k 3,207 shares | -4% | |
| 50Moderate | EXASbuy EXACT SCIENCES CORP | Kevin T Conroy President and CEO | $1.0M 19,500 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.